EP

CAD ACS & AMI

EDU

CLINICAL CARDIOLOGY

Accredited Symposium

Accredited Symposium

OPTIMIZING ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION - EXPERTS ON THE CASE

Co-Chair(s)

• 

  Jason Andrade, MD, FRCPC

  Associate Professor
  Vancouver General Hospital
  University of British Columbia
• 

  Laurent Macle, MD, FRCP(C), FHRS

  Cardiac Electrophysiologist
  Institut de Cardiologie de Montréal
  CHRS

Presenter(s)

• 

  Paul Dorian, MD MSc

  Professor of Medicine
  Division of Cardiology, University of Toronto
  St. Michael’s Hospital
• 

  Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

  Co-Director and Associate Head
  Canadian VIGOUR Centre and St. Michael's Hospital
  University of Toronto and University of Alberta
• 

  Isabelle Nault, MD, FRCPC

  Cardiologist Electrophysiologist
  Institut Universitaire de Cardiologie Et de Pneumologie de Québec
  Université Laval

Planning Committee Member(s)

• 

  Isabelle Nault, MD, FRCPC

  Cardiologist Electrophysiologist
  Institut Universitaire de Cardiologie Et de Pneumologie de Québec
  Université Laval
• 

  Paul Dorian, MD MSc

  Professor of Medicine
  Division of Cardiology, University of Toronto
  St. Michael’s Hospital
• 

  Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

  Co-Director and Associate Head
  Canadian VIGOUR Centre and St. Michael's Hospital
  University of Toronto and University of Alberta

This event is an accredited Group Learning Activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program and has been approved by the Canadian Cardiovascular Society. This program was co-developed with the Canadian Cardiovascular Society and BMS/Pfizer Alliance and was planned to achieve scientific integrity, objectivity and balance. This program was made possible through an educational grant from BMS/Pfizer Alliance.

Click here to view the program!

Learning Objectives

At the conclusion of this session, participants will be able to:

• identify the optimal antithrombotic treatment strategy for AF patients with ACS/PCI; and
• describe the efficacy and safety of oral anticoagulation therapy for stroke prevention in AF patients at higher risk of stroke and bleeding.